How Will Pancreatic, Prostate, and Endometrial Cancer Care Change by 2031?

At ESMO 2026, 3 leading oncology experts look ahead to how the treatment paradigms for pancreatic, prostate, and endometrial cancers could change over the next 5 years in this installment of The OncoloGIST from Targeted Onc.

Zev Wainberg, MD, UCLA Health, predicts a major shift in pancreatic cancer, where he expects every patient to receive a RAS inhibitor at some point. Wainberg anticipates that several RAS inhibitors will become available, used either alone or in iterative combinations, and moved earlier in the line of therapy. As that happens, he says chemotherapy will continue to be pushed further down the road, which he considers an overall positive development for patients.

Tamim Niazi, MDCM, Jewish General Hospital and McGill University, reflects on how prostate cancer treatment has evolved significantly over the past 10 years. He highlights the many agents in the pipeline, including new targeting approaches, radiation therapies, and systemic therapies. Although prostate cancer remains a serious disease, Niazi notes that cure and control rates have improved drastically, and he expects further significant gains in the next 5 years, making this a promising time for patients.

Brian Slomovitz, MD, Mount Sinai Medical Center, outlines the key questions that will shape endometrial cancer care. He calls for prospective evaluation of immunotherapy (IO) after IO, since current assumptions rely largely on retrospective data. Slomovitz also stresses the need to better overcome IO resistance, even in the mismatch repair–deficient (dMMR) population. He points to WRN helicase inhibitors and combinations of IO with antibody-drug conjugates as promising directions.

Watch the full video to hear each expert’s outlook on where pancreatic, prostate, and endometrial cancer treatment is headed.